Spero Therapeutics, Inc. (SPRO)
1.12
+0.02
(+1.82%)
USD |
NASDAQ |
Oct 19, 16:00
1.12
0.00 (0.00%)
After-Hours: 16:13
Spero Therapeutics Cash from Operations (Annual) : -12.62M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -12.62M |
| December 31, 2024 | -23.44M |
| December 31, 2023 | -33.00M |
| December 31, 2022 | -7.731M |
| December 31, 2021 | -64.35M |
| December 31, 2020 | -85.87M |
| Date | Value |
|---|---|
| December 31, 2019 | -50.02M |
| December 31, 2018 | -39.62M |
| December 31, 2017 | -39.11M |
| December 31, 2016 | -28.96M |
| December 31, 2015 | -9.608M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Inovio Pharmaceuticals, Inc. | -88.63M |
| Fortress Biotech, Inc. | -71.34M |
| Kura Oncology, Inc. | -64.06M |
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |